Suppressing a prostaglandin receptor may curb ferroptosis through itaconate
Suppressing prostaglandin E2 receptor EP2 may make resident macrophages release itaconate, protecting muscle, heart and lung cells from ferroptosis despite blocked neutrophil uptake. No increase in natural itaconate flux would refute this link.
Stage of verification
- Hypothesis published2026-09-30
- Indirect evidenceAssessed at 4 of 10
- Direct testAwaited
Map of the hypothesis
Hover over an icon or tap it to see its name.
Where in the body
Ageing mechanism
Kind of knowledge gap
A double ring marks the main placement where a group contains several values.
Target map
Every target of every published hypothesis, each with the actions a hypothesis can propose on it. The targets and the actions of this hypothesis are drawn solid.

Receptor or channel
EP2 receptor
A receptor whose activity can be suppressed
Where this hypothesis actsResident macrophages while neutrophil engulfment remains blocked
Hypotheses on this target 5
Lower level
Higher level
Blockade5
Agonism
Desensitisation
Function restoration
Function preservation

What is proposed
Blockade
Suppress EP2 to promote itaconate-mediated protection of neighboring cells
With whatNot stated in the record
HowNot stated in the record
Possible result
Possible functional improvement across organs despite persistent neutrophils and their damaging products
From the recordПодавление EP2 предположительно меняет метаболизм резидентных макрофагов

Rhythm or programme
Ferroptosis
Iron-dependent cell death caused by lipid peroxidation
Where this hypothesis actsMuscle, heart and lung cells exposed to neutrophil-associated inflammatory damage
Hypotheses on this target 2
Inhibition1
Activation
Function preservation
Feedback restoration
Rhythm restoration
Direct measurement

What is proposed
Inhibition
Suppress ferroptosis directly in target cells
With whatNot stated in the record
HowDirect suppression in target cells during continued blockade of neutrophil engulfment; the intervention is not specified
Possible result
Possible restoration of functional benefits lost after macrophage-specific ACOD1 inactivation
From the recordпрямое подавление ферроптоза в клетках-мишенях восстанавливает его при продолжающейся блокаде поглощения.

Enzyme
ACOD1
An enzyme involved in itaconate synthesis
Where this hypothesis actsMacrophages during EP2 suppression and blockade of neutrophil engulfment
Hypotheses on this target 1
Inhibition1
Activation
Lower level
Higher level
Replacement
Protection from degradation
Cofactor removal
Synthesis suppression
Function preservation

What is proposed
Inhibition
Inactivate ACOD1 specifically in macrophages
With whatControlled genetic model
HowConditional, macrophage-specific inactivation; the implementation is not stated
Possible result
Expected loss of the functional benefit if macrophage-derived itaconate is required
From the recordМакрофаг-специфическое выключение фермента синтеза итаконата ACOD1 устраняет этот выигрыш
All targets of the lab
Every target read from the published hypotheses, each kind around its pictogram. A larger mark means more hypotheses act on that target. Point at a mark and the actions proposed on it branch out of it.
Solid and named: the targets of this hypothesis
Explore in depth
The logic
The train of thought that ends in this hypothesis. Each stage is the reason the next exists. The master question narrows to a goal, the goal to an unknown nobody has closed, the unknown to the hypothesis proposed here. Every step below says what it rests on and what carries it.
Muscle, heart and lung cells might suffer less damage even while the immune cells contributing to that damage remain nearby. The unexpected move is to propose that treatment makes the receiving cells harder to kill, rather than requiring the removal of the damaging cells. This is a hypothesis generated by the pipeline, not a measured result.
- Suppressing EP2 is proposed to change the chemical activity of tissue-resident macrophages.
- Those macrophages are proposed to increase production and release of naturally made itaconate.
- Released itaconate is proposed to make neighboring tissue cells more resistant to iron-dependent oxidative damage to membrane fats.
- A comparable inflammatory burden is predicted to kill fewer tissue cells even while neutrophil engulfment remains blocked.
- Reduced tissue-cell death is predicted to leave less lasting loss of muscle, heart and lung function.
A floor might suffer less damage from the same number of muddy boots because its protective coating has changed, even if the boots are never removed.
Where the picture breaks: The proposal does not describe a physical coating. Living cells could change both their resistance and the surrounding inflammatory activity, so continued neutrophil presence alone cannot establish that the damaging burden stayed the same.
- Master questionstep 01 of 04
Aging processes may reinforce one another, so changing a shared cause might benefit several body systems at once.
Rests on: The goal seeks a single intervention with benefits across several systems and takes interacting aging processes as its starting premise.
AssumptionThe goal assumes that a shared causal link exists and can be changed precisely enough to produce benefits across several systems; the supplied material does not establish that general proposition.
- Goal pillarstep 02 of 04
Recovery should resist becoming trapped in a lasting damaged state.
Rests on: The search for a shared cause of aging is narrowed to the persistence of damage after recovery should have occurred.
AssumptionThe chain takes resistance to a lasting damaged state as a useful route toward the broader goal, without explaining why this particular property is the shared cause to target.
- Gap questionstep 03 of 04
Benefits from suppressing EP2 might survive even when removal of neutrophils, immune cells involved in inflammation, cannot recover; that would challenge the necessity of removing those cells.S6
Rests on: The supplied abstract from Science (2026), S6, reports that reducing EP2 signaling in tissue-resident macrophages, immune cells that live in tissues and engulf other cells, restored neutrophil removal and prevented stress in neighboring cells. It does not establish protection when that removal is blocked, or show that all forms of cleanup would then be unnecessary.
Supported by literature - Hypothesisstep 04 of 04
Suppressing EP2 is proposed to change macrophage chemistry so that released itaconate protects neighboring muscle, heart and lung cells from ferroptosis, a form of cell death driven by iron-dependent oxidative damage to membrane fats. The predicted benefit is less lasting loss of function despite continued neutrophil presence and blocked neutrophil engulfment.S2S3
Rests on: The preceding question creates a place for protection that does not require neutrophil removal. A review in American Journal of Translational Research (2024), S2, summarizes research connecting itaconate with protection against ferroptosis in experimental lung injury, but does not establish the EP2 connection or protection passed from resident macrophages to neighboring cells. Cell Death Discovery (2022), S3, reports that a chemically modified form of itaconate and a ferroptosis-blocking compound reduced oxidative damage to membrane fats and injury in cultured macrophages; this does not establish release or action of naturally produced itaconate in neighboring muscle, heart or lung cells.
Supported by literature
What is carried, and what is not. Screened literature supports pieces of the rationale, including a relationship between EP2 signaling and neutrophil removal and research connecting itaconate-related treatments with reduced ferroptosis, but no supplied source establishes the proposed sequence from EP2 suppression through macrophage release of natural itaconate to protection across muscle, heart and lung. The direction also depends on the setting: Cell Proliferation (2026), S1, reports that inhibiting aconitate decarboxylase 1 (ACOD1), the enzyme identified here as producing itaconate, reduced ferroptosis in treated muscle precursor cells, but it did not test the proposed macrophage-to-neighbor route and therefore neither establishes nor directly refutes that route.S1
Where the reasoning is carried by something unstated · 2
- Master question. The goal assumes that a shared causal link exists and can be changed precisely enough to produce benefits across several systems; the supplied material does not establish that general proposition.
- Goal pillar. The chain takes resistance to a lasting damaged state as a useful route toward the broader goal, without explaining why this particular property is the shared cause to target.
How a result here could mislead · 3
- Protection could be credited to greater tissue-cell resistance when the damaging exposure actually fell. Similar neutrophil numbers do not establish similar harmful activity, and blocking uptake of whole cells does not establish that their released products remain. What closes it: Confirm that neutrophil engulfment remains blocked and measure neutrophil numbers alongside complement activity, the activity of an immune protein cascade, and extracellular elastase, a protein-cutting enzyme outside cells. The proposed comparisons must also distinguish removal of released particles and increased production of inflammation-ending chemicals from protection against an unchanged damaging burden; comparable exposure needs a criterion fixed before the results are examined.
- Less oxidative damage to membrane fats could be read as proof of less ferroptosis, while protection from a modified itaconate compound could be read as proof that macrophages supplied the natural substance. What closes it: The stated test requires several independent signs of ferroptosis and isotope tracing, which follows an identifiable atomic label through substances, to separate itaconate production and transfer from the receiving cells' response. It also requires confirming that macrophage-specific ACOD1 removal reduces the relevant natural itaconate supply, then testing whether direct ferroptosis suppression restores protection; the supplied design does not specify the independent signs or their decision criteria.
- Early improvement in muscle or an average across organs could be mistaken for durable benefit across the body while damaging cells move elsewhere and later harm the heart or lungs. What closes it: Muscle, heart and lung function must be followed separately over time, alongside the location of neutrophils and evidence of new damage. The supplied proposal does not specify a follow-up duration or a rule for deciding whether improvement in one organ is outweighed by deterioration in another.
What would make this wrong. The proposal explicitly identifies failure of EP2 suppression to increase the flow of naturally produced itaconate as a falsifier of its proposed connection. Its claim that macrophage-derived itaconate is necessary would also fail if protection remained after verified removal of that supply while neutrophil engulfment stayed blocked. A failure to achieve either intervention would leave the result ambiguous rather than break the mechanism.
What it would change. If the mechanism held, a shared route to preserving several tissues could lie in their resistance to inflammatory damage, and the search for an aging intervention would need to distinguish that resistance from successful removal of damaging cells or products. Persistence of benefit during blocked neutrophil engulfment would challenge the necessity of whole-cell removal, but would not by itself eliminate cleanup of released products as an explanation. Even the predicted loss-and-restoration result would leave lifespan extension, effects in humans and durability during aging unestablished; the proposed test does not specify its species or timescale.
Sources read · 10
LCN2-ACOD1 Signalling Affects the Post-Injury Regeneration of Skeletal Muscle Through Mediating Ferroptosis. · Cell proliferation · 2026
“The ACOD1 inhibitor attenuated mitochondria‐associated ferroptosis induced by LCN2 and alleviated the inhibitory effect of LCN2 on cell viability.”
Does not settle: The source does not examine EP2 suppression, resident macrophages, itaconate release to neighbouring cells, neutrophil uptake or persistence, SPV_6, cardiac or lung cells, or effects in human tissue. Its reported ACOD1 result is in LCN2-treated C2C12 myoblasts and injured mouse skeletal muscle.
Itaconate to treat acute lung injury: recent advances and insights from preclinical models. · American journal of translational research · 2024
“This review provides an in-depth summary of the mechanistic research of itaconate in the field of acute lung injury, including inducing autophagy, preventing ferroptosis and pyroptosis, shifting macrophage polarization to an anti-inflammatory M2 phenotype, inhibiting neutrophil activation, regulating epigenetic modifications, and repressing aerobic glycolysis.”
Does not settle: Текст не устанавливает связь подавления EP2 с итаконатом, роль резидентных макрофагов или передачу защиты соседним клеткам. Он не сообщает о мышечных или сердечных клетках, сохранении нейтрофилов при сниженной гибели клеток, SPV_6 либо независимости эффекта от поглощения нейтрофилов.
Itaconate inhibits ferroptosis of macrophage via Nrf2 pathways against sepsis-induced acute lung injury. · Cell death discovery · 2022
“In vitro experiments showed that both 4-OI and ferrostatin-1 inhibited LPS-induced lipid peroxidation and injury of THP-1 macrophage.”
Does not settle: Источник не исследует подавление EP2, выделение эндогенного итаконата резидентными макрофагами, защиту соседних мышечных, сердечных или лёгочных клеток, сохранение нейтрофилов либо показатель SPV_6.
Metabolic regulation of macrophage polarization in myocardial infarction: from mechanisms to targeted therapies. · Journal of translational medicine · 2026
“We highlight drug-targetable mediators-including lactate, succinate, α-KG, itaconate, kynurenine, and NAD⁺-linked pathways-and discuss how stage-specific targeting may suppress early injurious inflammation while promoting reparative remodeling.”
Does not settle: This review abstract does not establish EP2 suppression, itaconate secretion by resident macrophages, protection of neighboring muscle, cardiac, or lung cells from ferroptosis, effects independent of neutrophil uptake, or any effect on SPV_6.
Efferocytosis impairs pulmonary macrophage and lung antibacterial function via PGE2/EP2 signaling. · The Journal of experimental medicine · 2009
“Prostaglandin E2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptor-mediated increase in intracellular cyclic AMP.”
Does not settle: The supplied text does not establish effects of EP2 suppression on itaconate, ferroptosis, target-cell resistance, neutrophil persistence, SPV_6, or outcomes in muscle, heart, or lung cells.
Restored clearance of senescent neutrophils by tissue-resident macrophages limits organ aging. · Science (New York, N.Y.) · 2026
“Plasma proteomics implicated the liver as a major source of age-associated immune change, in which reduced TRM EP2 signaling rescued neutrophil efferocytosis and prevented paracrine stress in neighboring cells.”
Does not settle: The abstract does not establish itaconate involvement, ferroptosis or lipid peroxidation, target-cell chemical resistance, effects in muscle, heart, and lung cells, or an effect on SPV_6 independent of restored neutrophil efferocytosis.
Efferocytosis-induced prostaglandin E2 production impairs alveolar macrophage effector functions during Streptococcus pneumoniae infection. · Innate immunity · 2017
“Efferocytosis slightly decreased the phagocytosis of S. pneumoniae but greatly inhibited bacterial killing by AMs in a manner dependent on PGE2 production, activation of the EP2-EP4/cAMP/PKA pathway and inhibition of H2O2 production.”
Does not settle: Источник не исследует итаконат, ферроптоз, устойчивость соседних клеток, мышечные или сердечные клетки, нейтрофилы, SPV_6 либо независимость эффекта от поглощения нейтрофилов.
Signaling via macrophage G2A enhances efferocytosis of dying neutrophils by augmentation of Rac activity. · The Journal of biological chemistry · 2011
“Subsequent signaling by PGE 2 via EP2 receptors activated macrophage adenylyl cyclase and protein kinase A. These events, in turn, culminated in enhanced activity of Rac1, resulting in an increase in both the numbers of macrophages efferocytosing apoptotic cells and the numbers of cells ingested per macrophage.”
Does not settle: Источник не исследует подавление EP2, итаконат, ферроптоз, устойчивость мышечных, сердечных или лёгочных клеток к перекисному окислению липидов либо SPV_6. Он сообщает, что передача сигнала через EP2 усиливала поглощение апоптотических нейтрофилов макрофагами.
ACOD1-itaconate in macrophage attenuates oxidative stress and inflammation in benign airway stenosis by upregulating and transferring FTH1. · Redox biology · 2026
“These exosomal FTH1 are taken up by fibroblasts via SCARA5 receptors, leading to iron overload and subsequent ferroptosis.”
Does not settle: This source does not assess EP2 suppression, resident macrophages, neutrophil uptake, SPV_6, or muscle, cardiac, or lung target-cell survival.
Obesity suppresses neutrophil-dependent itaconate signaling promoting ferroptosis in acute pancreatitis. · Redox biology · 2026
“Our analyses focused primarily on neutrophils due to their prominent contribution to acute pancreatitis pathophysiology [ ]. However, ACOD1 expression was also detected in pancreatic macrophages and therefore, a cooperative role for macrophage-derived itaconate in maintaining redox balance and protecting against ferroptosis cannot be excluded.”
Does not settle: Источник описывает нейтрофилы и клетки поджелудочной железы у мышей с панкреатитом, а не подавление EP2 или резидентные макрофаги. Он не устанавливает эффект для мышечных, сердечных или лёгочных клеток, не оценивает сохранение нейтрофилов либо их продуктов и не сообщает о SPV_6 или поглощении нейтрофилов.
The gap this hypothesis explains
Two live hypotheses pull in opposite directions here, and the field has not chosen between them.
Does suppressing a cell signal still benefit several body systems when improved removal of worn-out immune cells is blocked?
Original wording · exactly as the pipeline generated it
Сохранится ли многосистемная польза подавления EP2, если избирательно воспрепятствовать восстановлению удаления нейтрофилов, и опровергнет ли такой результат очистку как общее причинное звено?
What this question is asking
The question asks whether improved removal of worn-out neutrophils, a type of immune cell, is necessary for benefits across several body systems. The intervention suppresses signaling through E prostanoid receptor subtype 2 (EP2) in tissue-resident macrophages, immune cells that live in tissues and remove cellular material. The comparison is between suppression that allows neutrophil removal to improve and the same suppression with that improvement selectively prevented. The question assumes that suppression improves both removal and several aspects of health in aged mice, while treating removal as a possible shared cause of those benefits. It also asks whether benefits persisting when improved removal is blocked would disprove that proposed causal explanation.
- E prostanoid receptor subtype 2 (EP2)
- A cell receptor through which prostaglandin E2 sends signals. The question concerns reducing its signaling in tissue-resident macrophages; the supplied sources report different consequences of this signaling in different settings.
- Prostaglandin E2
- A signaling molecule that acts through receptors including EP2. In the supplied sources, its signaling is linked to increased removal of dying cells, impaired bacterial killing, and protection against scarring, so its effects cannot be reduced to a single beneficial or harmful role.
- Neutrophils
- A type of immune cell. The question concerns removal of worn-out neutrophils, rather than their production or every function they perform.
- Senescent neutrophils
- The aged or worn-out neutrophils named in S1's title. The supplied material does not specify how that state was identified or whether it matches the dying-cell states studied in the other sources.
- Tissue-resident macrophages
- Immune cells that reside in tissues and can ingest cells and other material. They are the cells whose EP2 signaling was reduced in S1.
- Clearance
- Removal of cells or other material from a tissue. Here, the proposed causal step is improved removal of neutrophils; reduced accumulation alone would not specify how that reduction occurred.
- Programmed cell death
- An organized process through which cells die. The dying cells ingested in S6 should not automatically be treated as equivalent to every neutrophil described as senescent in S1.
- Mitochondrial fitness
- The functional condition of mitochondria, structures within cells involved in supplying usable energy. S1 reports preservation of this condition but the supplied quotation does not specify its measurement.
- Inflammation
- A tissue and immune response to injury or threats. Body-wide inflammation is one of S1's reported outcomes, while the question asks whether improved cell removal explains its reduction.
- Cognitive decline and frailty
- Cognitive decline means worsening abilities such as memory and thinking; frailty means increased vulnerability associated with reduced physical reserves. Both are outcomes named in S1, but their measurement criteria are not supplied.
- Hydrogen peroxide
- A reactive chemical involved in the bacterial-killing mechanism described in S5. That source links reduced production of it to impaired bacterial killing.
- Scarring
- Formation of fibrous tissue, also called fibrosis. S8 concerns a possible loss of protection against this process in the uterine lining.
- Selective prevention
- The question's assumed ability to stop improvement in neutrophil removal while keeping EP2 suppression effective and avoiding other changes that could explain the outcomes. The supplied sources do not establish that this separation was achieved.
- Necessary and sufficient causes
- A necessary step must occur for a particular benefit to occur under the stated conditions. A sufficient step can produce that benefit on its own; showing necessity does not establish sufficiency.
Suppressing EP2 improves neutrophil clearance and macrophage condition in aged mice and produces benefits across several body systems, with clearance proposed as their common causal link.
Neutrophils are immune cells, and tissue-resident macrophages are cells that can remove them as they become worn out. The assumption is that reducing signaling through a receptor on these macrophages improves their condition and removal work, alongside benefits elsewhere in the body. If established, that connection would provide the starting point for asking whether improved removal is required for those benefits.
S1 directly reports that reducing macrophage EP2 signaling in aged mice preserved mitochondrial fitness and prevented several adverse outcomes. Its title identifies restored clearance of senescent neutrophils as the subject, but the supplied abstract quotation does not detail that clearance result or establish its necessity for the broader benefits. S6 reports increased uptake of dying cells following EP2 activation in another setting, so a general claim that less EP2 signaling necessarily improves clearance is not supported. None of the supplied passages establishes clearance as the necessary common cause.S1S6
The same question asked without the part nothing read establishes:
- In aged mice, do the benefits of reducing EP2 signaling persist when improved neutrophil removal is selectively prevented?
- Which benefits of reducing EP2 signaling in aged mice require improved neutrophil removal?
- Benefits persist across systems If improved neutrophil removal were genuinely prevented while receptor suppression remained effective, persistent benefits would mean that this improvement was not necessary for those measured benefits under those conditions. That would challenge clearance restoration as their required common cause, while leaving possible contributions from existing clearance or other settings unresolved.
- Benefits disappear across systems Under the question's assumption of selective interference, losing the benefits would support a requirement for improved neutrophil removal. It would not by itself establish that removal is the sole cause or that improving removal alone is sufficient to produce those benefits.
- Some benefits persist and others disappear Under the same selectivity assumption, the outcomes would differ in their dependence on improved neutrophil removal. Clearance restoration could then explain some benefits without serving as a necessary common link for every measured system.
The proposed chain runs from reduced receptor signaling to improved removal of worn-out immune cells, then to less inflammation and better function across several body systems. If improved removal is necessary, blocking that improvement would interrupt the chain despite continued receptor suppression. If benefits persist, the proposed explanation would need to distinguish benefits that require improved removal from benefits that do not. Mistaking an accompanying change for a necessary cause would misidentify why the intervention works; assuming that receptor suppression always helps would also overlook the opposing effects reported in other biological settings.
Подавление EP2 улучшает очистку и состояние макрофагов у мышей, RL-1; необходимость очистки для общего устойчивого эффекта отдельно не установлена.
Воспаление и функции возвращаются в заданные диапазоны за дни или недели; повторные нагрузки сохраняют восстановление нескольких систем месяцами.
Требуется разорвать предполагаемую причинную цепь и проверить, исчезает ли многосистемная польза при сохранённом воздействии на EP2.
The mechanism it proposes
The engine's own statement of the hypothesis, in full.
Подавление EP2 предположительно меняет метаболизм резидентных макрофагов так, что выделяемый ими итаконат повышает устойчивость соседних клеток к железозависимой гибели вследствие перекисного окисления липидов, то есть ферроптозу. Нейтрофилы и их повреждающие продукты могут сохраняться, но одинаковая воспалительная нагрузка вызывает меньше гибели мышечных, сердечных и лёгочных клеток. Общее причинное звено находится в химической устойчивости клеток-мишеней к повреждению. Оно должно уменьшать SPV_6 независимо от восстановления поглощения нейтрофилов.
Testing and possible results
The prediction that would tell it apart
A hypothesis that predicts what its rivals predict is not worth running an experiment over. This is the observation on which this one differs.
При подавлении EP2 и блокаде поглощения нейтрофилов функции улучшаются на фоне сопоставимых количества нейтрофилов, активности комплемента и внеклеточной эластазы. Одновременно снижаются окисленные фосфолипиды и гибель паренхиматозных клеток. Макрофаг-специфическое выключение фермента синтеза итаконата ACOD1 устраняет этот выигрыш; прямое подавление ферроптоза в клетках-мишенях восстанавливает его при продолжающейся блокаде поглощения. Отсутствие увеличения потока природного итаконата после подавления EP2 опровергает предложенную связь.
States a measurable outcome; comparing rivals needs more conditions. The prediction specifies qualitative changes under stated conditions, loss and restoration of benefit, and an explicit rejection condition. No rival prediction is supplied. Only a bench experiment would settle it.
What testing it would take
The engine's own read on whether this is testable with methods that already exist.
Изотопное отслеживание итаконата, условное выключение ACOD1 и измерение перекисного окисления липидов позволяют разделить источник метаболита и ответ клеток-мишеней. Защиту необходимо подтвердить несколькими независимыми признаками ферроптоза. Производные итаконата сами по себе не доказывают действие природного вещества.
Other explanations
Every other hypothesis the engine wrote for the same gap, and the observation that would separate the two.
При подавлении EP2 и блокаде поглощения нейтрофилов функции улучшаются на фоне сопоставимых количества нейтрофилов, активности комплемента и внеклеточной эластазы. Одновременно снижаются окисленные фосфолипиды и гибель паренхиматозных клеток. Макрофаг-специфическое выключение фермента синтеза итаконата ACOD1 устраняет этот выигрыш; прямое подавление ферроптоза в клетках-мишенях восстанавливает его при продолжающейся блокаде поглощения. Отсутствие увеличения потока природного итаконата после подавления EP2 опровергает предложенную связь.
- What would separate them
Delaying neutrophil uptake may preserve vesicle-mediated complement inhibition predicts: При подтверждённом подавлении EP2 и одинаковом исходном повреждении блокада поглощения нейтрофилов дополнительно улучшает восстановление мышцы, сердца и лёгких. Этот дополнительный выигрыш исчезает при нейтрофил-специфическом выключении CD55 и возвращается после введения очищенных CD55-положительных везикул. Напротив, независимое ускорение удаления нейтрофилов при сохранённой блокаде EP2 ухудшает восстановление, если происходит до образования защитных везикул. Простое сохранение пользы при блокаде поглощения для подтверждения этой гипотезы недостаточно.
- What would separate them
Vesicle removal may limit damage from elastase shielded against its natural inhibitor predicts: При блокаде поглощения целых нейтрофилов эффект подавления EP2 сохраняется только при снижении количества везикул с активной эластазой. Возврат очищенной фракции таких везикул устраняет пользу; равное количество везикул с инактивированной эластазой этого не делает. При одинаковой активности против свободной эластазы малый ингибитор подавляет везикулярную протеазу и восстанавливает функции эффективнее крупного ингибитора. После отделения эластазы от поверхности размерная зависимость исчезает.
- What would separate them
Shared lipid synthesis in neutrophils and platelets may limit tissue damage predicts: Польза подавления EP2 сохраняется при блокаде поглощения нейтрофилов и сопровождается усилением образования липоксинов из изотопно меченного нейтрофильного предшественника. Тромбоцит-специфическое выключение 12-липоксигеназы устраняет этот эффект при сохранённых количестве нейтрофилов, активности CD55 на везикулах и потоке итаконата. Введение соответствующего продукта синтеза восстанавливает функции. Отсутствие зависимости от тромбоцитарного фермента при подтверждённом его выключении опровергает гипотезу.
- What would separate them
Neutrophil movement may shift damage between organs and mimic lasting recovery predicts: После подавления EP2 на фоне блокады поглощения меченые нейтрофилы исчезают из исходной ткани, но сохраняются в крови и обнаруживаются в удалённых органах. Раннее улучшение мышцы сопровождается отсроченным ухудшением лёгочной или сердечной функции после повторной обычной нагрузки. За заранее заданный период наблюдения согласованного функционального выигрыша трёх систем нет. Подтверждённое улучшение всех трёх систем на протяжении месяцев при отсутствии переноса клеточной нагрузки опровергает эту гипотезу.
What stands behind it
Which of the figures above have a study behind them, which are the engine's own, and what it would take to refute the hypothesis. This audit never judges the idea.
This hypothesis states no figure and cites no study, so there is nothing here to trace.
What it would take to refute it. Nothing already retrieved carries the prediction’s terms and it names no measurement this layer can route to a public dataset, so the bench is the residual — not a finding against it.
0 citation handles extracted; 1 Europe PMC search run; 0 records examined; 0 sources stored for enrichment, 0 with full text. A citation that did not resolve is a bibliographic failure, not proof that no such paper exists, and no hypothesis is blocked by this audit.